| XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer J Kim, E McMillan, HS Kim, N Venkateswaran, G Makkar, ... Nature 538 (7623), 114-117, 2016 | 196 | 2016 |
| Identifying drug-target selectivity of small-molecule CRM1/XPO1 inhibitors by CRISPR/Cas9 genome editing JE Neggers, T Vercruysse, M Jacquemyn, E Vanstreels, E Baloglu, ... Chemistry & biology 22 (1), 107-116, 2015 | 142 | 2015 |
| Target identification of small molecules using large-scale CRISPR-Cas mutagenesis scanning of essential genes JE Neggers, B Kwanten, T Dierckx, H Noguchi, A Voet, L Bral, K Minner, ... Nature Communications 9 (1), 502, 2018 | 110 | 2018 |
| The second-generation exportin-1 inhibitor KPT-8602 demonstrates potent activity against acute lymphoblastic leukemia T Vercruysse, J De Bie, JE Neggers, M Jacquemyn, E Vanstreels, ... Clinical Cancer Research 23 (10), 2528-2541, 2017 | 60 | 2017 |
| Functional genomics identifies metabolic vulnerabilities in pancreatic cancer DE Biancur, KS Kapner, K Yamamoto, RS Banh, JE Neggers, ASW Sohn, ... Cell metabolism 33 (1), 199-210. e8, 2021 | 55 | 2021 |
| Preclinical assessment with clinical validation of selinexor with gemcitabine and nab-paclitaxel for the treatment of pancreatic ductal adenocarcinoma AS Azmi, HY Khan, I Muqbil, A Aboukameel, JE Neggers, D Daelemans, ... Clinical Cancer Research 26 (6), 1338-1348, 2020 | 36 | 2020 |
| Human exportin-1 is a target for combined therapy of HIV and AIDS related lymphoma E Boons, E Vanstreels, M Jacquemyn, TC Nogueira, JE Neggers, ... EBioMedicine 2 (9), 1102-1113, 2015 | 30 | 2015 |
| Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q JE Neggers, BR Paolella, A Asfaw, MV Rothberg, TA Skipper, A Yang, ... Cell reports 33 (11), 2020 | 28 | 2020 |
| Heterozygous mutation of cysteine528 in XPO1 is sufficient for resistance to selective inhibitors of nuclear export JE Neggers, E Vanstreels, E Baloglu, S Shacham, Y Landesman, ... Oncotarget 7 (42), 68842, 2016 | 27 | 2016 |
| enAsCas12a enables CRISPR-directed evolution to screen for functional drug resistance mutations in sequences inaccessible to SpCas9 JE Neggers, M Jacquemyn, T Dierckx, BP Kleinstiver, HJ Thibaut, ... Molecular Therapy 29 (1), 208-224, 2021 | 11 | 2021 |
| Down-regulation of AR splice variants through XPO1 suppression contributes to the inhibition of prostate cancer progression A Aboukameel, I Muqbil, E Baloglu, W Senapedis, Y Landesman, ... Oncotarget 9 (82), 35327, 2018 | 11 | 2018 |
| Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q JE Neggers, BR Paolella, A Asfaw, MV Rothberg, TA Skipper, A Yang, ... Cell reports 36 (2), 2021 | 4 | 2021 |
| Target Identification of Small Molecules Using Large-Scale CRISPR–Cas Mutagenesis Scanning of Essential Genes B Kwanten, JE Neggers, D Daelemans Essential Genes and Genomes: Methods and Protocols, 43-67, 2022 | 1 | 2022 |
| Selective Inhibitors of Nuclear Export (SINE) Compounds Suppress Both HIV Replication and AIDS Related Lymphoma D Daelemans, E Boons, E Vanstreels, M Jacquemyn, TC Nogueira, ... Blood, The Journal of the American Society of Hematology 126 (23), 2751-2751, 2015 | 1 | 2015 |
| Compositions and methods for treating neoplasia A Aguirre, B Paolella, F Vazquez, JE Neggers US Patent App. 18/061,369, 2023 | | 2023 |
| Therapeutic efficacy of selective CDK7 inhibition in pancreatic cancer mediated by induction of R-loop formation, DNA replication stress and genomic instability A Yang, J Jiang, Z Li, KS Kapner, H Feng, KE Lowder, M Kuljanin, ... CANCER RESEARCH 82 (22), 38-38, 2022 | | 2022 |
| Abstract A057: Therapeutic efficacy of selective CDK7 inhibition in pancreatic cancer mediated by induction of R-loop formation, DNA replication stress and genomic instability A Yang, J Jiang, Z Li, KS Kapner, H Feng, KE Lowder, M Kuljanin, ... Cancer Research 82 (22_Supplement), A057-A057, 2022 | | 2022 |
| Abstract NG01: Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers harboring loss of chromosome 18q or 16q JE Neggers, B Paolella, A Asfaw, MV Rothberg, TA Skipper, R Kalekar, ... Cancer Research 81 (13_Supplement), NG01-NG01, 2021 | | 2021 |
| Abstract PO-011: Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in SMAD4 or CDH1-deleted cancers JE Neggers, BR Paolella, A Asfaw, MV Rothberg, TA Skipper, RL Kalekar, ... Cancer Research 80 (22_Supplement), PO-011-PO-011, 2020 | | 2020 |
| Synthetic lethal interaction between the ESCRT paralog enzymes VPS4A and VPS4B in cancers with chromosome 18q or 16q deletion J Neggers, B Paolella, A Asfaw, M Rothberg, T Skipper, R Kalekar, ... European Journal of Cancer 138, S8, 2020 | | 2020 |
